Diagnosis and treatment of Tropheryma whipplei infection in patients with inflammatory rheumatic disease : Data from the French Tw-IRD registry
Copyright © 2023 The Authors. Published by Elsevier Ltd.. All rights reserved..
OBJECTIVES: Tropheryma whipplei infection can manifest as inflammatory joint symptoms, which can lead to misdiagnosis of inflammatory rheumatic disease and the use of disease-modifying antirheumatic drugs. We investigated the impact of diagnosis and treatment of Tropheryma whipplei infection in patients with inflammatory rheumatic disease.
METHODS: We initiated a registry including patients with disease-modifying antirheumatic drugs-treated inflammatory rheumatic disease who were subsequently diagnosed with Tropheryma whipplei infection. We collected clinical, biological, treatment data of the inflammatory rheumatic disease, of Tropheryma whipplei infection, and impact of antibiotics on the evolution of inflammatory rheumatic disease.
RESULTS: Among 73 inflammatory rheumatic disease patients, disease-modifying antirheumatic drugs initiation triggered extra-articular manifestations in 27% and resulted in stabilisation (51%), worsening (34%), or improvement (15%) of inflammatory rheumatic disease. At the diagnosis of Tropheryma whipplei infection, all patients had rheumatological symptoms (mean age 58 years, median inflammatory rheumatic disease duration 79 months), 84% had extra-rheumatological manifestations, 93% had elevated C-reactive protein, and 86% had hypoalbuminemia. Treatment of Tropheryma whipplei infection consisted mainly of doxycycline plus hydroxychloroquine, leading to remission of Tropheryma whipplei infection in 79% of cases. Antibiotic treatment of Tropheryma whipplei infection was associated with remission of inflammatory rheumatic disease in 93% of cases and enabled disease-modifying antirheumatic drugs and glucocorticoid discontinuation in most cases.
CONCLUSIONS: Tropheryma whipplei infection should be considered in inflammatory rheumatic disease patients with extra-articular manifestations, elevated C-reactive protein, and/or hypoalbuminemia before disease-modifying antirheumatic drugs initiation or in inflammatory rheumatic disease patients with an inadequate response to one or more disease-modifying antirheumatic drugs. Positive results of screening and diagnostic tests for Tropheryma whipplei infection involve antibiotic treatment, which is associated with complete recovery of Tropheryma whipplei infection and rapid remission of inflammatory rheumatic disease, allowing disease-modifying antirheumatic drugs and glucocorticoid discontinuation.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:88 |
|---|---|
| Enthalten in: |
The Journal of infection - 88(2024), 2 vom: 21. Feb., Seite 132-138 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Caillet Portillo, Damien [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
9007-41-4 |
|---|
| Anmerkungen: |
Date Completed 07.02.2024 Date Revised 07.02.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.jinf.2023.12.010 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM366324489 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM366324489 | ||
| 003 | DE-627 | ||
| 005 | 20240207232203.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231227s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.jinf.2023.12.010 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1283.xml |
| 035 | |a (DE-627)NLM366324489 | ||
| 035 | |a (NLM)38141787 | ||
| 035 | |a (PII)S0163-4453(23)00596-0 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Caillet Portillo, Damien |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Diagnosis and treatment of Tropheryma whipplei infection in patients with inflammatory rheumatic disease |b Data from the French Tw-IRD registry |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 07.02.2024 | ||
| 500 | |a Date Revised 07.02.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2023 The Authors. Published by Elsevier Ltd.. All rights reserved. | ||
| 520 | |a OBJECTIVES: Tropheryma whipplei infection can manifest as inflammatory joint symptoms, which can lead to misdiagnosis of inflammatory rheumatic disease and the use of disease-modifying antirheumatic drugs. We investigated the impact of diagnosis and treatment of Tropheryma whipplei infection in patients with inflammatory rheumatic disease | ||
| 520 | |a METHODS: We initiated a registry including patients with disease-modifying antirheumatic drugs-treated inflammatory rheumatic disease who were subsequently diagnosed with Tropheryma whipplei infection. We collected clinical, biological, treatment data of the inflammatory rheumatic disease, of Tropheryma whipplei infection, and impact of antibiotics on the evolution of inflammatory rheumatic disease | ||
| 520 | |a RESULTS: Among 73 inflammatory rheumatic disease patients, disease-modifying antirheumatic drugs initiation triggered extra-articular manifestations in 27% and resulted in stabilisation (51%), worsening (34%), or improvement (15%) of inflammatory rheumatic disease. At the diagnosis of Tropheryma whipplei infection, all patients had rheumatological symptoms (mean age 58 years, median inflammatory rheumatic disease duration 79 months), 84% had extra-rheumatological manifestations, 93% had elevated C-reactive protein, and 86% had hypoalbuminemia. Treatment of Tropheryma whipplei infection consisted mainly of doxycycline plus hydroxychloroquine, leading to remission of Tropheryma whipplei infection in 79% of cases. Antibiotic treatment of Tropheryma whipplei infection was associated with remission of inflammatory rheumatic disease in 93% of cases and enabled disease-modifying antirheumatic drugs and glucocorticoid discontinuation in most cases | ||
| 520 | |a CONCLUSIONS: Tropheryma whipplei infection should be considered in inflammatory rheumatic disease patients with extra-articular manifestations, elevated C-reactive protein, and/or hypoalbuminemia before disease-modifying antirheumatic drugs initiation or in inflammatory rheumatic disease patients with an inadequate response to one or more disease-modifying antirheumatic drugs. Positive results of screening and diagnostic tests for Tropheryma whipplei infection involve antibiotic treatment, which is associated with complete recovery of Tropheryma whipplei infection and rapid remission of inflammatory rheumatic disease, allowing disease-modifying antirheumatic drugs and glucocorticoid discontinuation | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Inflammatory rheumatic diseases | |
| 650 | 4 | |a Tropheryma whipplei | |
| 650 | 4 | |a Whipple disease | |
| 650 | 7 | |a Glucocorticoids |2 NLM | |
| 650 | 7 | |a C-Reactive Protein |2 NLM | |
| 650 | 7 | |a 9007-41-4 |2 NLM | |
| 650 | 7 | |a Anti-Bacterial Agents |2 NLM | |
| 650 | 7 | |a Antirheumatic Agents |2 NLM | |
| 700 | 1 | |a Puéchal, Xavier |e verfasserin |4 aut | |
| 700 | 1 | |a Masson, Maëva |e verfasserin |4 aut | |
| 700 | 1 | |a Kostine, Marie |e verfasserin |4 aut | |
| 700 | 1 | |a Michaut, Alexia |e verfasserin |4 aut | |
| 700 | 1 | |a Ramon, André |e verfasserin |4 aut | |
| 700 | 1 | |a Wendling, Daniel |e verfasserin |4 aut | |
| 700 | 1 | |a Costedoat-Chalumeau, Nathalie |e verfasserin |4 aut | |
| 700 | 1 | |a Richette, Pascal |e verfasserin |4 aut | |
| 700 | 1 | |a Marotte, Hubert |e verfasserin |4 aut | |
| 700 | 1 | |a Vix-Portet, Justine |e verfasserin |4 aut | |
| 700 | 1 | |a Dubost, Jean-Jacques |e verfasserin |4 aut | |
| 700 | 1 | |a Ottaviani, Sébastien |e verfasserin |4 aut | |
| 700 | 1 | |a Mouterde, Gaël |e verfasserin |4 aut | |
| 700 | 1 | |a Grasland, Anne |e verfasserin |4 aut | |
| 700 | 1 | |a Frazier, Aline |e verfasserin |4 aut | |
| 700 | 1 | |a Germain, Vincent |e verfasserin |4 aut | |
| 700 | 1 | |a Coury, Fabienne |e verfasserin |4 aut | |
| 700 | 1 | |a Tournadre, Anne |e verfasserin |4 aut | |
| 700 | 1 | |a Soubrier, Martin |e verfasserin |4 aut | |
| 700 | 1 | |a Cavalie, Laurent |e verfasserin |4 aut | |
| 700 | 1 | |a Brevet, Pauline |e verfasserin |4 aut | |
| 700 | 1 | |a Zabraniecki, Laurent |e verfasserin |4 aut | |
| 700 | 1 | |a Jamard, Bénédicte |e verfasserin |4 aut | |
| 700 | 1 | |a Couture, Guillaume |e verfasserin |4 aut | |
| 700 | 1 | |a Arnaud, Laurent |e verfasserin |4 aut | |
| 700 | 1 | |a Richez, Christophe |e verfasserin |4 aut | |
| 700 | 1 | |a Degboé, Yannick |e verfasserin |4 aut | |
| 700 | 1 | |a Ruyssen-Witrand, Adeline |e verfasserin |4 aut | |
| 700 | 1 | |a Constantin, Arnaud |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t The Journal of infection |d 1982 |g 88(2024), 2 vom: 21. Feb., Seite 132-138 |w (DE-627)NLM012791822 |x 1532-2742 |7 nnns |
| 773 | 1 | 8 | |g volume:88 |g year:2024 |g number:2 |g day:21 |g month:02 |g pages:132-138 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.jinf.2023.12.010 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 88 |j 2024 |e 2 |b 21 |c 02 |h 132-138 | ||